BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23257898)

  • 1. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.
    Pinato DJ; Ramachandran R; Toussi ST; Vergine M; Ngo N; Sharma R; Lloyd T; Meeran K; Palazzo F; Martin N; Khoo B; Dina R; Tan TM
    Br J Cancer; 2013 Feb; 108(2):429-37. PubMed ID: 23257898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
    Périgny M; Hammel P; Corcos O; Larochelle O; Giraud S; Richard S; Sauvanet A; Belghiti J; Ruszniewski P; Bedossa P; Couvelard A
    Am J Surg Pathol; 2009 May; 33(5):739-48. PubMed ID: 19238077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study.
    Favier J; Meatchi T; Robidel E; Badoual C; Sibony M; Nguyen AT; Gimenez-Roqueplo AP; Burnichon N
    Mod Pathol; 2020 Jan; 33(1):57-64. PubMed ID: 31383958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
    Kappler M; Taubert H; Holzhausen HJ; Reddemann R; Rot S; Becker A; Kuhnt T; Dellas K; Dunst J; Vordermark D; Hänsgen G; Bache M
    Strahlenther Onkol; 2008 Aug; 184(8):393-9. PubMed ID: 18956515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL; Gillespie D; House P; Layfield L; Shelton C
    J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
    Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
    Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype phenotype correlation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma.
    Lomte N; Kumar S; Sarathi V; Pandit R; Goroshi M; Jadhav S; Lila AR; Bandgar T; Shah NS
    Fam Cancer; 2018 Jul; 17(3):441-449. PubMed ID: 29124493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
    Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas.
    Li M; Song J; Pytel P
    Folia Neuropathol; 2014; 52(3):234-42. PubMed ID: 25310734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
    López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
    Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
    van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
    Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
    Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
    Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
    PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The VHL-dependent regulation of microRNAs in renal cancer.
    Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
    BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Hippel-Lindau disease and endocrine tumour susceptibility.
    Woodward ER; Maher ER
    Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
    Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
    Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.